Rapport Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Rapport Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About RAPP
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform.
CEOAbraham N. Ceesay
CEOAbraham N. Ceesay
Employees69
Employees69
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded2022
Founded2022
Employees69
Employees69
RAPP Key Statistics
Market cap1.33B
Market cap1.33B
Price-Earnings ratio-10.06
Price-Earnings ratio-10.06
Dividend yield—
Dividend yield—
Average volume367.19K
Average volume367.19K
High today$28.10
High today$28.10
Low today$26.79
Low today$26.79
Open price$26.79
Open price$26.79
Volume47.12K
Volume47.12K
52 Week high$42.27
52 Week high$42.27
52 Week low$6.43
52 Week low$6.43
Stock Snapshot
The current Rapport Therapeutics(RAPP) stock price is $27.88, with a market capitalization of 1.33B. The stock trades at a price-to-earnings (P/E) ratio of -10.06.
As of 2026-01-14, Rapport Therapeutics(RAPP) stock has fluctuated between $26.79 and $28.10. The current price stands at $27.88, placing the stock +4.1% above today's low and -0.8% off the high.
The Rapport Therapeutics(RAPP)'s current trading volume is 47.12K, compared to an average daily volume of 367.19K.
In the last year, Rapport Therapeutics(RAPP) shares hit a 52-week high of $42.27 and a 52-week low of $6.43.
In the last year, Rapport Therapeutics(RAPP) shares hit a 52-week high of $42.27 and a 52-week low of $6.43.
Analyst ratings
100%
of 9 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own RAPP. This list is generated using Robinhood data, and it’s not a recommendation.